ITRMF (Iterum Therapeutics) Pretax Margin %: -2,268.46% (As of Sep. 2025)


What is Iterum Therapeutics Pretax Margin %?

Iterum Therapeutics ITRMF +18.86% Pretax Margin % is -2,268.46% as of Sep. 2025. The stock has 4 warning signs investors should review. Among 947 Biotechnology companies, Iterum Therapeutics ranks worse than 91.34% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Iterum Therapeutics's Pre-Tax Income for the three months ended in Sep. 2025 was $-8.85 Mil. Iterum Therapeutics's Revenue for the three months ended in Sep. 2025 was $0.39 Mil. Therefore, Iterum Therapeutics's pretax margin for the quarter that ended in Sep. 2025 was -2,268.46%.

The historical rank and industry rank for Iterum Therapeutics's Pretax Margin % or its related term are showing as below:

ITRMF' s Pretax Margin % Range Over the Past 10 Years
Min: -277529.73   Med: -8812.89   Max: -5701.18
Current: -6842.31

ITRMF's Pretax Margin % is ranked worse than
91.34% of 947 companies
in the Biotechnology industry
Industry Median: -90.63 vs ITRMF: -6842.31

Iterum Therapeutics  (OTCPK:ITRMF) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Iterum Therapeutics Pretax Margin % Related Terms

Iterum Therapeutics Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Iterum Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iterum Therapeutics Pretax Margin % Chart

Iterum Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Iterum Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -2,268.46

ITRMF vs ENSC, PPCB, REVB: Pretax Margin % Comparison

For the Biotechnology subindustry, Iterum Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Iterum Therapeutics Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Iterum Therapeutics's Pretax Margin % falls into.


Iterum Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Iterum Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-24.534/0
= %

Iterum Therapeutics's Pretax Margin for the quarter that ended in Sep. 2025 is calculated as

Pretax Margin=Pre-Tax Income (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=-8.847/0.39
=-2,268.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of -2,268.46% mean?
Iterum Therapeutics (ITRMF) has a Pretax Margin % of -2,268.46% as of Sep. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Iterum Therapeutics and its competitors. According to the industry distribution chart, Iterum Therapeutics ranks #865 out of 947 companies in the Biotechnology industry, placing it in the top 91.3%.
Is Iterum Therapeutics' Pretax Margin % too high?
Iterum Therapeutics' current Pretax Margin % is -2,268.46%. Based on the distribution chart, Iterum Therapeutics ranks #865 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Iterum Therapeutics' Pretax Margin % compare to ENSC and PPCB?
According to the Biotechnology industry distribution chart, Iterum Therapeutics ranks #865 out of 947 companies for Pretax Margin %. This places Iterum Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Iterum Therapeutics and its competitors. Iterum Therapeutics's current Pretax Margin % is -2,268.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current Pretax Margin % of -2,268.46%. The current Pretax Margin % is -2,268.46%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current Pretax Margin % is -2,268.46% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Iterum Therapeutics Business Description

Address 3 Dublin Landings, North Wall Quay, Dublin 1, Dublin, IRL, D01 C4E0
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.